RepliCel Life Sciences Inc. – OTC:REPCF
RepliCel Life Sciences stock price today
RepliCel Life Sciences stock price monthly change
RepliCel Life Sciences stock price quarterly change
RepliCel Life Sciences stock price yearly change
RepliCel Life Sciences key metrics
Market Cap | 5.71M |
Enterprise value | 3.65M |
P/E | -1.48 |
EV/Sales | 10.33 |
EV/EBITDA | -0.95 |
Price/Sales | 13.15 |
Price/Book | -0.53 |
PEG ratio | N/A |
EPS | N/A |
Revenue | 353.73K |
EBITDA | -1.60M |
Income | 399.80K |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -1087.55% |
Oper. margin | -418.5% |
Gross margin | 0% |
EBIT margin | -418.5% |
EBITDA margin | -453.71% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRepliCel Life Sciences stock price history
RepliCel Life Sciences stock forecast
RepliCel Life Sciences financial statements
| Jun 2023 | 88.43K | -558.15K | -631.15% |
|---|---|---|---|
| Sep 2023 | 88.43K | -818.60K | -925.67% |
| Dec 2023 | 88.43K | 2.02M | 2293.7% |
| Mar 2024 | 88.43K | -251.83K | -284.77% |
| Jun 2023 | 495649 | 6.54M | 1321.24% |
|---|---|---|---|
| Sep 2023 | 331465 | 6.96M | 2102.34% |
| Dec 2023 | 287786 | 4.81M | 1674.39% |
| Mar 2024 | 202527 | 4.98M | 2461.52% |
| Jun 2023 | -430.00K | 0 | -42.49K |
|---|---|---|---|
| Sep 2023 | -200.28K | 0 | -1 |
| Dec 2023 | 337.49K | 0 | -293.56K |
| Mar 2024 | -160.12K | 17.25K | 100.36K |
RepliCel Life Sciences other data
| Insider | Compensation |
|---|---|
Mr. R. Lee Buckler B.Ed., L.L.B., LLB (1966) Pres, Chief Executive Officer, Corporation Sec. & Director | $188,200 |
Mr. Simon S. Ma CPA, B.A., CA (1965) Chief Financial Officer & Director of Fin. | $75,280 |
Dr. Kevin John McElwee Ph.D. (1970) Chief Scientific Officer | $23,520 |
-
What's the price of RepliCel Life Sciences stock today?
One share of RepliCel Life Sciences stock can currently be purchased for approximately $0.11.
-
When is RepliCel Life Sciences's next earnings date?
Unfortunately, RepliCel Life Sciences's (REPCF) next earnings date is currently unknown.
-
Does RepliCel Life Sciences pay dividends?
No, RepliCel Life Sciences does not pay dividends.
-
How much money does RepliCel Life Sciences make?
RepliCel Life Sciences has a market capitalization of 5.71M.
-
What is RepliCel Life Sciences's stock symbol?
RepliCel Life Sciences Inc. is traded on the OTC under the ticker symbol "REPCF".
-
What is RepliCel Life Sciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of RepliCel Life Sciences?
Shares of RepliCel Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are RepliCel Life Sciences's key executives?
RepliCel Life Sciences's management team includes the following people:
- Mr. R. Lee Buckler B.Ed., L.L.B., LLB Pres, Chief Executive Officer, Corporation Sec. & Director(age: 59, pay: $188,200)
- Mr. Simon S. Ma CPA, B.A., CA Chief Financial Officer & Director of Fin.(age: 60, pay: $75,280)
- Dr. Kevin John McElwee Ph.D. Chief Scientific Officer(age: 55, pay: $23,520)
-
When RepliCel Life Sciences went public?
RepliCel Life Sciences Inc. is publicly traded company for more then 21 years since IPO on 3 Jun 2004.
-
What is RepliCel Life Sciences's official website?
The official website for RepliCel Life Sciences is replicel.com.
-
Where are RepliCel Life Sciences's headquarters?
RepliCel Life Sciences is headquartered at 570 Granville Street, Vancouver, BC.
-
How can i contact RepliCel Life Sciences?
RepliCel Life Sciences's mailing address is 570 Granville Street, Vancouver, BC and company can be reached via phone at +60 4 248 8730.
RepliCel Life Sciences company profile:
RepliCel Life Sciences Inc.
replicel.comOTC
0
Biotechnology
Healthcare
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Vancouver, BC V6C 3P1
CIK: 0001205059
ISIN: CA76027P4006
CUSIP: 76027P400
